Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 20:11:1098434.
doi: 10.3389/fped.2023.1098434. eCollection 2023.

Prevention and management of CMV infection in pediatric solid organ transplant recipients

Shanthi S Balani  1 , Sanober Sadiq  2 , Chelsey J Jensen  3 , Sarah J Kizilbash  1
Affiliations
Review

Prevention and management of CMV infection in pediatric solid organ transplant recipients

Shanthi S Balani et al. Front Pediatr. .

Abstract

Human cytomegalovirus (CMV) remains one of the most common opportunistic infections following solid organ transplantation in children. CMV causes morbidity and mortality through direct tissue-invasive disease and indirect immunomodulatory effects. In recent years, several new agents have emerged for the prevention and treatment of CMV disease in solid organ transplant recipients. However, pediatric data remain scarce, and many of the treatments are extrapolated from the adult literature. Controversies exist about the type and duration of prophylactic therapies and the optimal dosing of antiviral agents. This review provides an up-to-date overview of treatment modalities used to prevent and treat CMV disease in solid organ transplant (SOT) recipients.

Keywords: cytomegalovirus emerging treatment; cytomegalovirus prevention; cytomegalovirus treatment; opportunistic infections; pediatric solid organ transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Hocker B, Zencke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, et al. . Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)Ganciclovir. Transplantation. (2016) 100:862–70. 10.1097/TP.0000000000000888 - DOI - PubMed
    1. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. . Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. (2008) 46:840–6. 10.1086/528718 - DOI - PubMed
    1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice. Clin Transplant. (2019) 33:e13512. 10.1111/ctr.13512 - DOI - PubMed
    1. Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant. (2002) 21:841–9. 10.1016/S1053-2498(02)00435-7 - DOI - PubMed
    1. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. (2007) 20:425–31. 10.1097/QCO.0b013e328259c33b - DOI - PubMed